Analyst picks & changes

Company

Bank

Analyst

Coverage

Opinion

Wk chg

6/20 cls

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN)

Maxim Group

Jason Kolbert

Price target

Buy

26%

$8.13

Kolbert raised his target to $22 from $6, driven by Achillion's ACH-3422 nucleotide prodrug inhibitor of HCV NS5B polymerase. He expects Phase I proof-of-concept data in 2H14. Kolbert also thinks Achillion's acquisition potential remains high. Earlier this month, Merck & Co. Inc. (NYSE:MRK) said it is acquiring HCV company Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) for $3.9B.

Actelion Ltd. (SIX:ATLN)

Jefferies

Peter Welford

Price target

Buy

25%

CHF113.50